Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of QY201 tablets in adults with moderate-to-severe atopic dermatitis
CTR20244696Phase 3Active
- Sponsor
- Origin Biosciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of qy201 in atopic dermatitis (AD), sponsored by Origin Biosciences. Started Mar 2025; status: active.
02
Drugs
qy201
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20244696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244696.